Encompass Health (NYSE:EHC) Price Target Cut to $62.00

Encompass Health (NYSE:EHCGet Rating) had its target price decreased by Credit Suisse Group from $63.00 to $62.00 in a research note issued to investors on Wednesday, MarketBeat.com reports. Credit Suisse Group currently has an outperform rating on the stock.

Several other research firms have also weighed in on EHC. Royal Bank of Canada reduced their price objective on shares of Encompass Health from $82.00 to $66.00 in a research report on Wednesday, August 24th. Barclays reduced their price objective on shares of Encompass Health from $80.00 to $63.00 and set an overweight rating for the company in a research report on Thursday, August 4th. Truist Financial reduced their price objective on shares of Encompass Health from $75.00 to $65.00 and set a buy rating for the company in a research report on Monday, August 8th. TheStreet lowered shares of Encompass Health from a b- rating to a c+ rating in a research report on Tuesday, June 28th. Finally, Raymond James reduced their price objective on shares of Encompass Health from $70.00 to $65.00 and set a strong-buy rating for the company in a research report on Thursday, August 4th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Encompass Health currently has an average rating of Buy and an average target price of $70.00.

Encompass Health Stock Down 2.3 %

Encompass Health stock opened at $48.87 on Wednesday. The stock has a market cap of $4.88 billion, a price-to-earnings ratio of 14.94, a PEG ratio of 2.43 and a beta of 1.02. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 1.29. The company’s 50-day moving average price is $50.78 and its two-hundred day moving average price is $59.30. Encompass Health has a 52 week low of $44.33 and a 52 week high of $78.31.

Encompass Health (NYSE:EHCGet Rating) last released its earnings results on Monday, August 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.08). The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.34 billion. Encompass Health had a net margin of 6.22% and a return on equity of 16.20%. The firm’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.17 EPS. On average, analysts expect that Encompass Health will post 2.88 EPS for the current fiscal year.

Encompass Health Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, October 17th. Stockholders of record on Monday, October 3rd will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date is Friday, September 30th. Encompass Health’s dividend payout ratio (DPR) is 34.25%.

Insider Transactions at Encompass Health

In other news, CEO Mark J. Tarr sold 20,449 shares of the stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $53.25, for a total value of $1,088,909.25. Following the completion of the sale, the chief executive officer now directly owns 440,895 shares of the company’s stock, valued at $23,477,658.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is owned by insiders.

Institutional Trading of Encompass Health

Hedge funds have recently made changes to their positions in the stock. Meeder Asset Management Inc. bought a new position in Encompass Health during the first quarter valued at approximately $33,000. Worth Asset Management LLC bought a new position in Encompass Health during the first quarter valued at approximately $35,000. Allworth Financial LP raised its position in Encompass Health by 83.1% during the first quarter. Allworth Financial LP now owns 630 shares of the company’s stock valued at $45,000 after acquiring an additional 286 shares in the last quarter. Rather & Kittrell Inc. bought a new position in Encompass Health during the fourth quarter valued at approximately $49,000. Finally, Eagle Bay Advisors LLC raised its position in Encompass Health by 137.5% during the second quarter. Eagle Bay Advisors LLC now owns 1,019 shares of the company’s stock valued at $57,000 after acquiring an additional 590 shares in the last quarter. 93.07% of the stock is owned by hedge funds and other institutional investors.

About Encompass Health

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

See Also

Analyst Recommendations for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.